Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy: Molecular imaging as a clinical tool in the burgeoning era of personalized medicine

Ramon Barajas, Kenneth Krohn, Jeanne Link, Randall A. Hawkins, Jennifer L. Clarke, Miguel H. Pampaloni, Soonmee Cha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.

Original languageEnglish (US)
Article number24
JournalBiomedicines
Volume4
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Molecular imaging
Precision Medicine
Positron emission tomography
Molecular Imaging
Glioma
Positron-Emission Tomography
Medicine
Imaging techniques
Bioelectric potentials
Medical imaging
Magnetic resonance
Therapeutics
Tumors
Blood
Diagnostic Imaging
fluoromisonidazole
Monitoring
Disease Progression
Magnetic Resonance Imaging

Keywords

  • ADC
  • Bevacizumab
  • FMISO
  • Glioma
  • MRI
  • PET
  • Progression
  • Pseudoprogression
  • Reduced diffusion

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy : Molecular imaging as a clinical tool in the burgeoning era of personalized medicine. / Barajas, Ramon; Krohn, Kenneth; Link, Jeanne; Hawkins, Randall A.; Clarke, Jennifer L.; Pampaloni, Miguel H.; Cha, Soonmee.

In: Biomedicines, Vol. 4, No. 4, 24, 01.12.2016.

Research output: Contribution to journalArticle

@article{ca219cda1b8f4de898e80d606cb73dd1,
title = "Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy: Molecular imaging as a clinical tool in the burgeoning era of personalized medicine",
abstract = "The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.",
keywords = "ADC, Bevacizumab, FMISO, Glioma, MRI, PET, Progression, Pseudoprogression, Reduced diffusion",
author = "Ramon Barajas and Kenneth Krohn and Jeanne Link and Hawkins, {Randall A.} and Clarke, {Jennifer L.} and Pampaloni, {Miguel H.} and Soonmee Cha",
year = "2016",
month = "12",
day = "1",
doi = "10.3390/biomedicines4040024",
language = "English (US)",
volume = "4",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "4",

}

TY - JOUR

T1 - Glioma FMISO PET/MR imaging concurrent with antiangiogenic therapy

T2 - Molecular imaging as a clinical tool in the burgeoning era of personalized medicine

AU - Barajas, Ramon

AU - Krohn, Kenneth

AU - Link, Jeanne

AU - Hawkins, Randall A.

AU - Clarke, Jennifer L.

AU - Pampaloni, Miguel H.

AU - Cha, Soonmee

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.

AB - The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy. Three distinct features were observed from this small cohort of patients. First, the presence of pseudoprogression was retrospectively associated with the absence of hypoxia. Second, a subgroup of patients with recurrent high grade glioma undergoing bevacizumab therapy demonstrated disease progression characterized by an enlarging nonenhancing mass with newly developed reduced diffusion, lack of hypoxia, and preserved cerebral blood volume. Finally, a reduction in hypoxic volume was observed concurrent with therapy in all patients with recurrent tumor, and markedly so in two patients that developed a nonenhancing reduced diffusion mass. This case series demonstrates how medical imaging has the potential to influence personalized medicine in several key aspects, especially involving molecular PET imaging for personalized diagnosis, patient specific disease prognosis, and therapeutic monitoring.

KW - ADC

KW - Bevacizumab

KW - FMISO

KW - Glioma

KW - MRI

KW - PET

KW - Progression

KW - Pseudoprogression

KW - Reduced diffusion

UR - http://www.scopus.com/inward/record.url?scp=85052613891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052613891&partnerID=8YFLogxK

U2 - 10.3390/biomedicines4040024

DO - 10.3390/biomedicines4040024

M3 - Article

AN - SCOPUS:85052613891

VL - 4

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 4

M1 - 24

ER -